Adrenomyeloneuropathy| A Pipeline Analysis Report 2018| Technavio
LONDON--(BUSINESS WIRE)--Jul 9, 2018--Technavio has announced its latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat adrenomyeloneuropathy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005753/en/
Technavio has published a new report on the drug development pipeline for adrenomyeloneuropathy, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Adrenomyeloneuropathy: Market overview
Adrenomyeloneuropathy is the adult onset of adrenoleukodystrophy, which is a genetic disease that affects the adrenal glands and the nervous system. The mutation of the ABCD1 gene can lead to adrenomyeloneuropathy that affects the spinal cord. It also leads to behavioral abnormalities, vision loss, and hearing problems. Males are more vulnerable to adrenomyeloneuropathy than females.
According to a senior analyst at Technavio , “The mean age for the onset of adrenomyeloneuropathy is 28-60 years. Some of the symptoms of adrenomyeloneuropathy include weight loss, progressive stiffness, and weakness of the legs, ataxia, nausea, and hypertonia. Adrenomyeloneuropathy is usually inherited from family. The treatments for this disease include steroid replacement therapy, physical therapy, and medications.”
Adrenomyeloneuropathy: Segmentation analysis
This market research report segments the adrenomyeloneuropathy market based on therapies employed (monotherapy and unknown), RoA (intravenous, oral, and unknown), therapeutic modalities (small molecule, gene therapy, stem cell, and unknown), targets (thyroid hormone beta receptor subtype, PPAR gamma, microglia cells, NFkB cells, and unknown), MoA (gene replacement, thyroid hormone beta receptor subtype agonist, PPAR gamma agonist, cell replacement, microglia cells activator, NFkB cells inhibitor, and unknown), and recruitment status (recruiting, completed, not yet recruiting, active not recruiting, unknown, and NA).
Monotherapy includes the use of a single drug to treat a particular disorder. In the current pipeline, 12 molecules are used as monotherapy.
In case of therapeutic modality, the small molecule segment held the largest share of the market, accounting for more than 46% of the market share. Small molecules are chemically manufactured active substances that enter the cells easily because of their low molecular weight of 900 Daltons.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic Modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005753/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH GENETICS PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/09/2018 01:51 PM/DISC: 07/09/2018 01:51 PM